Literature DB >> 17958943

Acting on voices: Omnipotence, sources of threat, and safety-seeking behaviours.

David Hacker1, Max Birchwood, Jeremy Tudway, Alan Meaden, Catherine Amphlett.   

Abstract

OBJECTIVES: Previous research indicates that beliefs about voice power and omnipotence are associated with distress, depression, and compliance. The present study investigates whether acting on voices to mitigate perceived threat, in a broader sense than compliance, is driven by delusional beliefs, as the Chadwick, Birchwood, and Trower cognitive-behavioural model of voices would suggest. The role of safety behaviours in maintaining beliefs about voice omnipotence and distress is also examined.
DESIGN: A cross-sectional investigation of 30 individuals with current experience of auditory verbal hallucinations was conducted.
METHOD: Participants were assessed on self-report measures of voice topography, voice-related threat and distress, safety behaviour use, beliefs about voices, and depression and anxiety.
RESULTS: Three sources of threat were identified: physical harm, shame, and loss of control. Twenty-six individuals had recently used safety behaviours, believing them to be effective in threat reduction. The degree of safety behaviour use and voice-related distress were associated with voice omnipotence beliefs; mood or voice characteristics did not account for this relationship. The association of safety behaviours with increased distress was mediated by beliefs about voice omnipotence.
CONCLUSIONS: Acting on voices can be conceptualized as a form of safety seeking, associated with maintaining beliefs about voice omnipotence and distress.

Entities:  

Mesh:

Year:  2007        PMID: 17958943     DOI: 10.1348/014466507X249093

Source DB:  PubMed          Journal:  Br J Clin Psychol        ISSN: 0144-6657


  6 in total

1.  Capturing coping with symptoms in people with a diagnosis of schizophrenia: introducing the MACS-24.

Authors:  Maarten Bak; Philippe Delespaul; Lydia Krabbendam; Karola Huistra; Wil Walraven; Jim van Os
Journal:  Int J Methods Psychiatr Res       Date:  2009       Impact factor: 4.035

2.  Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.

Authors:  D H Nieman; A L Sutterland; J Otten; H E Becker; M L Drent; M van der Gaag; M Birchwood; L de Haan
Journal:  BMJ Case Rep       Date:  2011-02-09

3.  The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.

Authors:  Moogeh Baharnoori; Cali Bartholomeusz; Aurelie A Boucher; Lisa Buchy; Christopher Chaddock; Bonga Chiliza; Melanie Föcking; Alex Fornito; Juan A Gallego; Hiroaki Hori; Gisele Huf; Gul A Jabbar; Shi Hyun Kang; Yousri El Kissi; Jessica Merchán-Naranjo; Gemma Modinos; Nashaat A M Abdel-Fadeel; Anna-Karin Neubeck; Hsiao Piau Ng; Gabriela Novak; Olasunmbo O Owolabi; Diana P Prata; Naren P Rao; Igor Riecansky; Darryl C Smith; Renan P Souza; Renate Thienel; Hanan D Trotman; Hiroyuki Uchida; Kristen A Woodberry; Anne O'Shea; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2010-10-08       Impact factor: 4.939

Review 4.  Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia?

Authors:  Dina Collip; Inez Myin-Germeys; Jim Van Os
Journal:  Schizophr Bull       Date:  2008-01-18       Impact factor: 9.306

5.  The CHALLENGE trial: the effects of a virtual reality-assisted exposure therapy for persistent auditory hallucinations versus supportive counselling in people with psychosis: study protocol for a randomised clinical trial.

Authors:  L C Smith; L Mariegaard; D L Vernal; A G Christensen; N Albert; N Thomas; C Hjorthøj; L B Glenthøj; M Nordentoft
Journal:  Trials       Date:  2022-09-13       Impact factor: 2.728

6.  A relationship of sorts: gender and auditory hallucinations in schizophrenia spectrum disorders.

Authors:  Stefanie Suessenbacher-Kessler; Andrea Gmeiner; Tamara Diendorfer; Beate Schrank; Annemarie Unger; Michaela Amering
Journal:  Arch Womens Ment Health       Date:  2021-03-20       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.